Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7